What is known about effectiveness and safety At present, there is limited high-quality clinical evidence showing that commercially available GLP-1 patches lead to meaningful weight loss or blood sugar improvement
If gastrointestinal symptoms are significantly impacting quality of life, GPs may consider temporarily reducing the dose or extending the interval between dose increases
ReproSil-Pur) at 200 nl min 1 and analyzed on an Orbitrap Eclipse with FAIMS (compensation voltages: 45, 60 and 75)
El Sharouni M-A, Stodell M, Ahmed T, et al
In fact, high-profile examples of payers pulling back on coverage are stacking up: North Carolinas state health plan dropped GLP-1s after spending $100 million, Ascension eliminated all weight-loss drug coverage, and Mayo Clinic capped lifetime GLP-1 benefits at $20,000